StreetInsider.com News Articles

Form S-3/A Elicio Therapeutics,

Mon, 02 Mar 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260302/26091996.html

Form S-3/A Elicio Therapeutics,

Mon, 02 Mar 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260302/26091996.html

Form S-3 Elicio Therapeutics,

Fri, 27 Feb 2026 16:23:00 -0500

si-local-file:///var/storage/secattach/20260227/26082130.html

Form S-3 Elicio Therapeutics,

Fri, 27 Feb 2026 16:23:00 -0500

si-local-file:///var/storage/secattach/20260227/26082130.html

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Wed, 25 Feb 2026 08:00:00 -0500

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46^th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA.

TD Cowen 46^th Annual Health Care Conference
Format: Company presentation
Date: Wednesday, March 4, 2026
Time: 1:10 PM ET

The live webcast and replay of the presentation will be

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Wed, 25 Feb 2026 08:00:00 -0500

TD Cowen 46^th Annual Health Care Conference
Format: Company presentation
Date: Wednesday, March 4, 2026
Time: 1:10 PM ET

The live webcast and replay of the presentation will be

Elicio Therapeutics Reports Inducement Grants

Wed, 18 Feb 2026 08:00:00 -0500

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on February 17, 2026, Elicio granted an aggregate of 30,300 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

Elicio Therapeutics Reports Inducement Grants

Wed, 18 Feb 2026 08:00:00 -0500

Form 4 Elicio Therapeutics, For: Feb 02 Filed by: Connelly Robert

Tue, 03 Feb 2026 16:42:00 -0500

si-local-file:///var/storage/secattach/20260203/25939792.html

Form 4 Elicio Therapeutics, For: Feb 02 Filed by: Connelly Robert

Tue, 03 Feb 2026 16:42:00 -0500

si-local-file:///var/storage/secattach/20260203/25939792.html

Form 4 Elicio Therapeutics, For: Feb 02 Filed by: Shah Preetam

Tue, 03 Feb 2026 16:40:00 -0500

si-local-file:///var/storage/secattach/20260203/25939753.html

Form 4 Elicio Therapeutics, For: Feb 02 Filed by: Shah Preetam

Tue, 03 Feb 2026 16:40:00 -0500

si-local-file:///var/storage/secattach/20260203/25939753.html

Form 4 Elicio Therapeutics, For: Feb 02 Filed by: DeMuth Peter

Tue, 03 Feb 2026 16:39:00 -0500

si-local-file:///var/storage/secattach/20260203/25939704.html

Form 4 Elicio Therapeutics, For: Feb 02 Filed by: DeMuth Peter

Tue, 03 Feb 2026 16:39:00 -0500

si-local-file:///var/storage/secattach/20260203/25939704.html

Form 4 Elicio Therapeutics, For: Feb 02 Filed by: Haqq Christopher

Tue, 03 Feb 2026 16:34:00 -0500

si-local-file:///var/storage/secattach/20260203/25939558.html

Form 4 Elicio Therapeutics, For: Feb 02 Filed by: Haqq Christopher

Tue, 03 Feb 2026 16:34:00 -0500

si-local-file:///var/storage/secattach/20260203/25939558.html

Elicio Therapeutics Reports Inducement Grants

Fri, 16 Jan 2026 08:00:00 -0500

BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

Elicio Therapeutics Reports Inducement Grants

Fri, 16 Jan 2026 08:00:00 -0500

Elicio Therapeutics Reports Inducement Grants

Tue, 16 Dec 2025 08:00:00 -0500

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on December 15, 2025, Elicio granted an aggregate of 157,193 inducement stock options to three new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

Elicio Therapeutics Reports Inducement Grants

Tue, 16 Dec 2025 08:00:00 -0500

Elicio reports immune response expansion in cancer trial

Thu, 11 Dec 2025 08:00:32 -0500

Elicio Therapeutics Inc. (NASDAQ: ELTX) announced that 87% of evaluated patients in its ongoing Phase 2 AMPLIFY-7P trial demonstrated T cell responses to tumor antigens beyond the targeted mKRAS mutations after treatment with ELI-002 7P.

The company analyzed 15 patients from the 90-patient trial to assess antigen spreading, a process where the immune system expands its response from initial target antigens to additional tumor-specific antigens. The analysis used direct ex vivo assays on 5-12 tumor neoantigens per patient.

According to the company's statement, 13 of the 15 evaluated patients showed significant expansion of T cells targeting non-mKRAS tumor neoantigens. The responses included

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Thu, 11 Dec 2025 08:00:00 -0500

Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy
87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapy
The induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more adaptable, and personalized anti-tumor response

BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Thu, 11 Dec 2025 08:00:00 -0500

Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy
87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapy
The induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more adaptable, and personalized anti-tumor response

BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the

Form 4 Elicio Therapeutics, For: Dec 09 Filed by: DeMuth Peter

Wed, 10 Dec 2025 17:05:00 -0500

si-local-file:///var/storage/secattach/20251210/25724711.html

Form 4 Elicio Therapeutics, For: Dec 09 Filed by: DeMuth Peter

Wed, 10 Dec 2025 17:05:00 -0500

si-local-file:///var/storage/secattach/20251210/25724711.html